Island's $6.4B, Precision Neuro's $250M & the AI Control-Point Bet
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Island's $6.4B, Precision Neuro's $250M & the AI Control-Point Bet
-
ナレーター：
-
著者：
(00:01:10) AI Defensibility: Models to Moats
(00:01:41) Pilgrim's Biosurveillance Seed Round
(00:02:24) Precision Neuroscience's $250M Round
(00:02:54) Kasvu, Basecamp, and Biotech Bets
(00:03:39) Semiconductor Power Delivery and Closing Watchpoints
Capital is rotating. Not toward AI applications, but toward the control points that govern them — and today's stories map exactly where institutional money is landing.
Island raised $400M at a $6.4B valuation, up sharply from $4.8B just months ago. The repricing reflects a specific thesis: as AI agents operate through browsers alongside humans, the browser becomes the one surface where security policy, compliance, and access management can actually be enforced. Evolution Equity is betting that operational moat — deep IT integrations, procurement relationships, compliance infrastructure — is worth more than any algorithmic advantage right now.
Precision Neuroscience closed $250M backed by Pershing Square and ARK Invest, funding the transition from research settings to clinical deployment for minimally invasive neural implants. The 'minimally invasive' framing is deliberate — it's the commercial wedge into hospital systems and insurance coverage.
Pilgrim closed a $25M seed for ARGUS, an environmental biosurveillance platform combining air sampling with genomic sequencing. Buckley Ventures led, with backing connected to Anthropic's red-team community. Biological threat detection is being framed as recurring infrastructure.
In biotech, Helsinki-based Kasvu raised €30M Series A for a neuroplasticity compound targeting TrkB receptors — the psychedelic mechanism, without the psychedelic experience. Basecamp Research closed $140M Series C for AI-driven drug discovery trained on proprietary biological data.
Two Chinese semiconductor raises — Langxi Technology and Puxi Optoelectronics — signal that AI performance scaling is now constrained by power delivery and packaging, not raw compute density.
Watchpoints: whether Island's browser thesis becomes standard Fortune 500 procurement, and whether Pilgrim generates a replicable biosurveillance commercial framework.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません